CDK9 and diffuse large B-cell lymphoma: Here we present a potential all-oral combination regimen consisting of a novel CDK9 inhibitor, voruciclib and the BCL-2 specific inhibitor, venetoclax, with promise for treating this high-risk subtype of DLBCL.